01 9Equa/EquMet
02 6Galvus
03 4Galvus Group
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 391
2019 Revenue in Millions : 75
Growth (%) : 421
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 391
2019 Revenue in Millions : 75
Growth (%) : 421
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 1,199
2019 Revenue in Millions : 1,297
Growth (%) : -8
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 322
2020 Revenue in Millions : 391
Growth (%) : -6
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 322
2020 Revenue in Millions : 391
Growth (%) : -6
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 1,092
2020 Revenue in Millions : 1,199
Growth (%) : -9
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 272
2021 Revenue in Millions : 322
Growth (%) : -16
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 272
2021 Revenue in Millions : 322
Growth (%) : -16
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 859
2021 Revenue in Millions : 1,092
Growth (%) : -21
Main Therapeutic Indication : Diabetes
Currency : USD
2023 Revenue in Millions : 210
2022 Revenue in Millions : 251
Growth (%) : -6
LOOKING FOR A SUPPLIER?